Merck & Co.'s Keytruda revenue 2014-2023
Keytruda is not only Merck & Co.’s top product but also one of the best-selling drugs worldwide, generating over 25 billion U.S. dollars in revenue during 2025. The cancer drug with the generic name pembrolizumab increased its revenues for around four billion U.S. dollars compared to 2022.